About: AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; Jazz Pharmaceuticals plc to develop T-cell engaging (TCE) multispecific antibodies; partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc.; and Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.
Sector: Healthcare
Industry: Biotechnology
Latest price: $12.27 (-6.19%)
ABCL NASDAQ Abcellera Biologics Inc
Abcellera Biologics Inc share price
ABCL price activity
Last Price
$12.270
Change (24hr)
-0.81 USD (6.19%)
Volume
3.86M
Volume (4w avg)
-
Open
$12.60
Day Range
$11.75 - $12.91
Previous Close
$13.08
Last Trade
30 Oct, 8:09 pm GMT+0
Delayed
30 Oct, 8:09 pm GMT+0
ABCL price performance
Delayed
30 Oct, 8:09 pm GMT+0
ABCL Market Signals